GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3

Stock Information for GT Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About GT Biopharma Inc.

GT Biopharma Reports Full Year 2025 Financial Results
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
THE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material Cycle
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.